1. Introduction
Thiamine, or vitamin B1, is an essential co-factor of glucose metabolism in almost all living organisms, and a modulator of neuronal and neuromuscular transmission in vertebrates. In human cells, the active form is thiamine diphosphate, which plays an important role as a co-factor in various metabolic pathways [1,2,3].
The SLC19A3 gene, encoding thiamine transporter-2 (THTR2), is located in the 36.3 position of the q arm of chromosome 2; the gene has six exons and 13 putative enhancer regions. THTR2 is an SLC (solute carrier)-type thiamine transporter [4,5], and mutations in the SLC19A3 gene are responsible for extremely rare diseases, biotin-responsive basal ganglia disease and related encephalopathy—see [4]. However, genetic variants and a complex regulation of cellular thiamine transport may play a role in various metabolic disorders. High blood glucose down-regulates THTR2, probably through the Sp1 (specificity protein 1) transcription factor in human renal proximal tubular epithelium [6,7]. Two single nucleotide polymorphisms (SNPs) in the SLC19A3 gene were also found to be associated with protection against diabetic retinopathy and nephropathy in type 1 diabetes [6,8]. Subsequent in vitro work showed that reduced thiamine availability, in combination with high glucose, impairs thiamine transport primarily via THTR2, both in the retinal and renal cells involved in diabetic microangiopathy [8,9,10]. In the case of THTR2 deficiency, there is no systemic decrease in the thiamine levels, and such a decrease can only be detected in the cerebrospinal fluid [4].
Thiamine uptake by THTR2 was found to be sensitive to changes in pH and the electrochemical gradient, as well as to various drugs [11]. Metformin, widely used as a first-line therapy for type 2 diabetes (T2DM), was shown to be a competing substrate for THTR2-dependent thiamine uptake. Phenformin, chloroquine, verapamil, famotidine and amprolium were also found to inhibit THTR2-mediated uptake of both thiamine and metformin [11]. Thus, THTR2 may play a role in the intestinal absorption and tissue distribution of metformin, as well as for other organic cationic compounds, making this transporter a target for drug–drug and drug–nutrient interactions [5,11,12,13].
The role of THTR2 activity and the potentially related polymorphisms in the SLC19A3 gene in diabetes have been already suggested [4,8,10], and in our current work we decided to explore in detail the potential genetic alterations modulating THTR2 transporter activity in metabolic diseases. In this work we first focused on T2DM, and identified four major, potentially disease-associated haplotypes in the SLC19A3 gene. To further explore the metabolic significance of these haplotypes, we analyzed their association with clinical laboratory parameters in T2DM patients. Our findings suggest that SLC19A3 gene variations may also be implicated in gout (arthritis urica, AU), another metabolic disorder characterized by elevated serum uric acid levels. The deposition of urate crystals in joint tissues induces an inflammatory response, leading to clinical manifestations of gout. T2DM and gout may be connected, as increased insulin concentrations promote uric acid reabsorption through the regulation of ABCG2 (ATP binding cassette G2) or the URAT1 (urate transporter 1) transporters, reducing urinary uric acid extraction and increasing serum uric acid levels [14]. Based on these data, we have also performed an analysis of potential SLC19A3 gene alterations in patients with the renal overload type of gout [15].
These findings offer new insights into the genetic regulation of THTR2 transporter activity and its potential involvement in metabolic disorders. By identifying clinically relevant SLC19A3 haplotypes and their effects on gene expression, our study enhances the understanding of the metabolic background of T2DM and gout, shedding light on their underlying pathomechanisms. These results may contribute to advancing disease comprehension and support the development of targeted therapeutic strategies in the future.
2. Results
2.1. In Silico Haplotype and SNP Analysis in SLC19A3
By using the 1000 Genomes (1000 G) project [16], we identified and characterized 111 SNPs in SLC19A3 potentially associated with T2DM (for details see Section 4). These SNPs were analyzed by LDlink, and we identified four large haplotypes (H1, H2, H3, H4) in the related regions (Figure 1). One of these haplotypes (H1) was in exonic regions, and H2–4 were in the predicted promoter regions. Regarding these haplotypes, in each one we identified lead SNPs, then we examined the frequency of the minor variants of these SNPs among control and metabolic disease patients.
Haplotype 1 (H1) includes three exonic regions without a predicted enhancer region. Based on bioinformatic studies, no transcription factor (TF) binding site was found within this haplotype. The minor allele frequency (MAF) value of this minor variant is very low (MAF = 0.01), and due to this low allele frequency, further examination of the haplotype was not performed here (for details see Figure S1 and Table S1).
Haplotype 2 (H2) includes the predicted promoter region and enhancer 5, containing 12 SNPs (Figure S2 and Table S2) The MAF value for the lead SNP of this minor variant is 0.2445, and three SNPs in these regions have a total of 96 potential TF binding sites. The predicted transcription factors are involved in embryonic development (HOX genes) [17] or in the regulation of the nervous system (FoxB1, RAX2) [18,19], but factors affecting the function of the immune system also appear (EBF genes, PROX1, STAT5, RFX1) [20,21,22,23]. There are also binding sites for several transcription factors associated with glucose metabolism, such as NR1H4, RORC, NR2C1 (Table S3) [24,25,26].
In this work, we designated rs6436729 as lead SNP for the minor variant of H2, because most of the potential regulatory factors are predicted to bind to this site (Table S3). The Haplotype variants showed a Hardy–Weinberg equilibrium (HWE, p = 0.9784, with Chi-square tests), and the respective MAFs were q(T) = 0.2156, in our sample set (262 samples of studied individuals) (Table S4). Interestingly, the minor allele is mostly T in Europe but A in Africa and Asia.
Haplotype 3 (H3) is the largest haplotype examined in terms of the number of polymorphisms, encompassing 36 SNPs. It is located in the 3rd and 4th enhancer regions of the gene (Figure S3, Tables S5 and S6). In H3, we selected rs34241868 as lead SNP for the minor variant, an intronic variant with a MAF value of 0.1829. The Haplotype variants showed a Hardy–Weinberg equilibrium (p = 0.9422, with Chi-square tests), and the respective MAFs were q(A) = 0.0935, in our sample set (Table S4).
In the region of H3, 12 transcription factors are predicted to bind. In the presence of the H3 minor variant, including rs17372552, the Nr5a2 TF cannot bind to this site. This TF plays an important role in bile acid synthesis, cholesterol homeostasis and triglyceride synthesis [27]; thus, the minor variant may cause a potential alteration in these metabolic processes. Another important TF with altered binding to the minor variant in the region of rs34241868, is KLF13 (Kruppel-like transcription factor 13), which has been shown to be a repressive TF in the Sp/KLF family. KLF13 competes with Sp1 for binding to GC boxes and plays a role in B- and T-cell development; thus, the presence of the minor allele may affect the immune system (Table S6) [28,29].
Haplotype 4 (H4) is located in the enhancer regions 1, 7, 8, and 9, and contains 21 SNPs (Figure S4 and Table S7). There are 54 predicted transcription factor binding sites in this region (Table S8) The selected lead SNP for the minor variant is rs55975119, which is an intronic variant. The MAF value for this SNP is 0.102. The Haplotype variants showed a Hardy–Weinberg equilibrium (p = 0.6510, with Chi-square tests), and the respective MAFs were q(A) = 0.2080, in our sample set (Table S4).
The predicted TFs binding sites in H4 are mainly involved in hormonal balance (ESR2, NR3C1, NR3C2) [30,31], while GATA-1 [32] and DDIT3 [33] play an important role in erythroid development. The TFs potentially binding to this region, STAT1, Arid5a, and IRF9, play an important role in antiviral immunity (Table S8) [34,35,36].
2.2. Experimental SNP Analysis in T2DM Patients—Correlations with Laboratory Data
When analyzing the clinical data in 66 T2DM patients (25 male and 41 female) and 54 age-matched control individuals (29 male and 25 female), as expected, we found that the abdominal circumference, body mass index (BMI), blood glucose, blood insulin, Homeostasis Model Assessment (HOMA) index or hemoglobin A1C (HbA1c), red blood cells (RBC) and white blood cells (WBC) levels were significantly higher in the T2DM patient group, as compared to the control individuals—see Table S9. In order to explore the potential role of the haplotypes in T2DM, we examined the SNPs in the DNA samples of the control and T2DM patients, and analyzed the potential correlation of the minor variants with the key physical and laboratory parameters.
In the case of Haplotype 2, the lead SNP, rs6436729 was analyzed in T2DM patients and controls. We found no significant deviation from the published MAF values in either of these groups (CTRL: 0.1944, T2DM: 0.25). The HWE values were similar in both groups (CTRL: 0.7814, T2DM: 0.7044) (Table S10). The laboratory data showed no significant differences between the individuals carrying the wild-type and the minor variant, respectively, either in the CTRL or in the T2DM group (Table S11).
In the case of Haplotype 3, the MAF value of the examined lead SNP (rs34241868) in the CTRL group was similar to that in the NCBI data (Table S12). The MAF values in the T2DM patient group (0.2045) appeared higher than those in the CTRL group (0.1759), while this difference was not statistically significant. The HWE value appeared to be lower in the T2DM (0.5684) group than in the CTRL group (0.8913), but again, this difference was not statistically significant.
In the following, we analyze the key physical and laboratory parameters with or without the presence of MV of H3 (Table S13). Although blood glucose and blood insulin levels were somewhat higher in the presence of this minor variant in the T2DM group, these differences were not statistically significant (p = 0.0756 and p = 0.0571, respectively—see Table S13B). However, importantly, the HOMA value (reflecting insulin resistance and β-cell function) was significantly higher in T2DM patients carrying H3-MV (p = 0.0189). Also, the HbA1c level, a key indicator for long-term glucose overload, was significantly higher in T2DM patients carrying H3-MV, as compared to patients carrying the wild type allele (p = 0.0102). In the control individuals, the presence of H3-MV did not significantly affect this laboratory parameter (Table S14 and Figure 2).
Interestingly, in the control group the abdominal circumference was significantly lower in individuals carrying the minor variant, as compared to those with the wild type alleles (p = 0.0186). This parameter in T2DM patients was not different with or without the presence of H3-MV (Table S13B). Other clinical parameters, such as uric acid, inflammatory factors were not significantly different between T2DM patients and the control individuals, regarding the presence or absence of H3-MV (Table S13).
In the case of Haplotype 4, the lead SNP, rs55975119 was analyzed in T2DM patients and controls (Table S15). We found no significant deviation from the published MAF values in either of these groups (CTRL: 0.1018, T2DM: 0.106). The HWE values appeared lower in the T2DM group (0.6601), compared to the control group (0.9198), but this difference was not statistically significant.
The physical parameters were not significantly different in the examined groups (Table S16). Interestingly, in the control individuals the blood glucose level was significantly lower in the presence of H4-MV, (p = 0.0474), while this difference was not observed in the T2DM patients (Table S16B). We did not find any differences in the blood insulin, HOMA or HbA1c levels in the studied groups. However, as shown in Table S17 and Figure 3, uric acid levels were significantly lower in the T2DM group of patients carrying H4-MV (p = 0.0008). Among the parameters indicating inflammation, the white blood cell count was significantly higher in the T2DM patients carrying H4-MV, as compared to the patients with the wild type allele (p = 0.0272). The uric acid levels and the WBC counts were similar in the control individuals with or without the presence of H4-MV (Table S17, Figure 3). Other clinical inflammatory parameters were not significantly different in any of the examined groups (Table S16).
2.3. Experimental SNP Analysis in Gout Patients—Correlation with Laboratory Data
We examined the four SLC19A3 haplotypes in 76 renal overload gout patient (AU) (69 male and 7 female) and 66 age-matched controls (57 male and 9 female) from the same clinic, and analyzed the key labor parameters, such as uric acid (UA), urea, creatinine, red blood cells count (RBC), white blood cells count (WBC), erythrocyte sedimentation rates (ESR), and inflammatory factors. As expected, among these parameters the uric acid levels and the ESR values were significantly higher in the AU group, as compared to the controls. In the case of AU patients, we performed a detailed analysis of the potential correlations of the minor haplotype variants and the laboratory parameters (Table S18).
In the case of Haplotype 2, the lead SNP, rs6436729 was analyzed (Table S19) and we found no significant deviation from the published MAF values in these groups (CTRL: 0.1918, AU: 0.2105). The HWE values were similar in both groups (CTRL: 0.9864, AU: 0.9835).
Interestingly, the laboratory data showed that the ESR values were significantly lower (p = 0.0113) in the control patients with H2-MV. No other clinical parameters showed significant correlation with the H2 haplotype, either in the AU patients or the control individuals (Table S20).
In the case of Haplotype 3, the MAF value in the CTRL group was similar to the literature data (Table S21). The MAF value in the AU patient group (0.2632) was somewhat higher than in the control group (0.1986), but this difference was not statistically significant. The HWE values were similar in both groups (CTRL: 0.8908, AU: 0.9939).
Among the examined laboratory parameters (Table S22), the basophil granulocyte% value was significantly higher in the AU group with H3-MV (p = 0.0273), while there was no such difference in the control group (Table S23 and Figure 4). Other clinical laboratory parameters showed no significant differences in this regard (Table S22).
In the case of Haplotype 4, the lead SNP, rs55975119 was analyzed (Table S24) and the MAF values were lower in both groups (CTRL: 0.089, AU: 0.0724), as compared to the published MAF values (0.1024), but these differences were not statistically significant. The HWE values were apparently lower in the AU group (0.4304), as compared to the control group (0.7278), but again, this difference was not statistically significant.
In the following, we analyze the key physical and laboratory parameters in the presence of H4-MV (Table S25). In the control subjects, in the presence of H4-MV, the mean value of ESR was significantly lower (p = 0.0241), while in the AU group carrying this MV a similar tendency was observed, although not reaching statistical significance (p = 0.0752). Interestingly, in the relevant control group the lymphocyte% (p = 0.0186), eosinophil% (p = 0.0308) and creatine levels (p = 0.0299) were significantly lower, while the neutrophil counts were higher (p = 0.0299) in individuals with H4-MV. In the group of AU patients these differences were not statistically different (Table S25).
2.4. Analysis of the Effects of the Selected Haplotypes on Gene Expression in a Luciferase Reporter Assay
In these experiments, we examined the effects of the lead SNP regions of Haplotype 3 (rs34241868) and Haplotype 4 (rs55975119), on gene expression in HEK293 and MCF7 cells, by using a dual-luciferase reporter assay. The effects of thiamine, the antidiabetic drug metformin, and fedratinib (a THTR2 inhibitor) were also studied under normal and thiamine-deficient conditions in the HEK293 cell line.
First, we examined the effect of H3-MV (rs34241868 SNP) on luciferase expression. As shown in Figure 5A and Figure S5, when the WT or the minor variant form of the SLC19A3 cDNA was inserted into the Renilla luciferase vector, we observed very low luciferase expression in both HEK293 and MCF7 cells, as compared to the thymidine kinase (TK) promoter-containing control vector. In the MCF7 cell line, we did not observe any difference in luciferase expression between the WT or the minor variant constructs (Table S26). However, in HEK293 cells, significantly higher expressions from the H3-MV containing construct could be observed, as compared to the wild type construct (p = 0.0351—Figure 5A). In HEK293 cells grown in thiamine-depleted media, a similar tendency was observed, while the expression levels were not significantly different between cells containing the WT or the minor variant of the rs34241868 construct (Figure 5B, first 2 columns, and Table S27). Also, in thiamine-depleted HEK293 cells the re-addition of high thiamine (B1) concentrations caused no significant differences in the expression levels driven by any of these constructs (Figure 5B, columns 3 and 4, Table S27). However, under similar conditions, in the case of the H3-MV construct, the addition of thiamine + metformin (last two columns) produced significantly higher luciferase expression (p = 0.0016) than that found in the case of the WT variant. Also, in this system, in the case of the H3-MV containing construct, metformin produced significantly lower expression levels (p = 0.0018, Figure 5B, column 2 vs. column 10). The addition of fedratinib, a JAK kinase inhibitor, either alone or together with thiamine, had no significant effect in this system (Figure 5B, columns 5–8).
In the following experiments, we investigated the effect of the rs55975119 SNP (Haplotype 4) in HEK293 and MCF7 cells, using a dual luciferase reporter assay (Figure S6 and Table S28). Similar to the H3 constructs, in this case we also found low luciferase expression levels compared to the control construct, containing the TK promoter. No differences in the expression levels between the H4 wild-type and H4-MV constructs were found in either of these cell types. The addition of excess thiamine, metformin or fedratinib to the cells did not cause significant changes in the luciferase expression levels. As shown in Figure 6 (and Table S29), in thiamin-depleted HEK293 cells, the addition of excess thiamine or metformin, or these two agents together, produced no alterations in the luciferase expression. However, under these conditions, the addition of fedratinib, together with excess thiamine, caused a significant decrease in luciferase expression only in cells expressing the wild-type form of H4, and not in the case of H4-MV (p = 0.04854).
3. Discussion
The malabsorption of thiamine (vitamin B1) results in the development of diseases mainly affecting the nervous system. The relatively rare serious conditions can be traced back to the failure of THTR proteins, caused by selected mutations [3,4,5]. The potential role of thiamine transporters in metabolic diseases, including T2DM, is an increasingly investigated area, especially regarding the absorption of vitamin B1 at the cellular level. Currently, diabetes research is mainly focusing on the role of OCT1 vitamin B1 transporter, as metformin treatment, the basic therapy for type 2 diabetes, primarily inhibits the OCT1 transporter [4,5,6,8,10,37,38].
While OCT1 (SLC22A1) is one of the key intestinal transporters of thiamine, various retino-, nephro- or neuropathic complications have also been linked to the THTR1 (SLC19A2) and the THTR2 (SLC19A3) transporters [5,6,11,12,37,38]. The complex role of these transporters in the development and treatments of metabolic diseases is currently mostly unexplored; therefore, in the present work, we have studied the potential relationship between the polymorphic variants of SLC19A3 and two metabolic diseases, diabetes and gout.
In this work, we first characterized the SLC19A3 gene variants using in silico bioinformatics methods, and identified four haplotypes (H1–H4) with potential relevance in THTR2 transporter expression. Three of these haplotypes (H2–H4) are located in the promoter region, with numerous potential TF binding sites; thus, these sites may function variably in the genetic variants. Based on our results, the Kruppel-like transcription factor 13 (KLF13) appears to be the most important of the predicted binding sites, located in Haplotype 3 (in the region around rs34241868), and is lost in the H3 minor variant.
KLF13 suppresses gene transcription by competing with the activator Sp1 factor; therefore, in H3-MV, an increased transporter expression may occur (indeed, as shown in the luciferase expression data, such an increased expression was found in HEK cells by H3-MV). SP1 protein expression increases in thiamine-deficient conditions, and Sp1 affects the expression level of SLC19A3 through a glucose-mediated pathway. This regulation is especially important in insulin-independent cells, including retinal capillary endothelium, pericytes and neuroretina, as these cells cannot regulate glucose uptake and are more vulnerable to hyperglycemic damage [8,28,29]. Thus, complications caused by hyperglycemic damage may occur more often in individuals carrying the H3 minor variant.
Since the minor variant SNPs in SLC19A3 may affect thiamine transport in complex metabolic conditions, here we studied the effects of these SLC19A3 gene variants in T2DM and gout patients, as well as their role in related gene expression in human cells by using a luciferase reporter assay.
In exploring the molecular genetic background of T2DM and AU patients, no accumulation of the minor variants of any of the haplotypes was observed. Still, when examining the relationship of laboratory parameters and the presence of these haplotypes, in the case of SLC19A3-H3 (lead SNP rs34241868), in T2DM we observed a significant correlation of two important parameters for diabetes monitoring, higher HOMA indices and higher HbA1c levels, in the presence of the minor variant (H3-MV). The HOMA index, derived from fasting glucose and insulin levels, reflects clinical insulin resistance, while HbA1c levels are key indicators for a long-term increase in blood glucose, affecting disease-related complications in T2DM patients.
According to these results, the presence of H3-MV in the SLC19A3 gene may dispose for a more pronounced diabetic condition. In T2DM patients, the presence of H3-MV also correlated with higher leukocyte numbers, an indicator of a chronic inflammation. Interestingly, in AU patients carrying H3-MV, we found a higher basophil leukocyte count, potentially reflecting a favorable condition, as basophil counts in AU patients are decreasing during the acute phase and normalized during remission [39].
Regarding Haplotype 4 (lead SNP rs55975119), the presence of the minor variant in T2DM patients showed a strong correlation with lower uric acid levels and higher leukocyte counts. In patients suffering from gout (AU), we found no such effect of H4-MV on uric acid levels, while the presence of this haplotype correlated with significantly lower ESR levels, eosinophil% and lymphocyte%.
In analyzing the effects of H2–H4 in T2DM and AU patients, we observed numerous potential effects of the minor variants, while—most probably because of the relatively low number of patients included in this study—these did not reach the level of statistical significance. Similar studies in larger metabolic disease patient groups should help to explore the clinical significance of our initial findings, presented here in the Supplements.
In order to better understand the potential cellular effects of the SLC19A3 haplo-types, in the following experiments we examined the effects of the H3 and H4 haplotypes in human model cell lines by using a dual-luciferase expression system. In these experiments, we found that in HEK293 cells luciferase expression driven by the H3 minor variant was significantly higher than the expression driven by H3-WT (although this difference was not detectable in the MCF7 cell line). In the case of HEK293 cells grown in thiamine-deficient media, in response to the addition of metformin, the luciferase activity of the cells expressing the H3-MV construct was significantly reduced, while no such difference was observed in HEK293 cells carrying the H3-WT construct. In addition, when metformin and vitamin B1 were added together to thiamine-depleted HEK293 cells, luciferase expression driven by the H3 wild-type construct was significantly decreased, while there was no such decrease in the case of the construct carrying H3-MV. These data indicate a significantly different response to thiamine and metformin in the presence of these H3 variants.
In the case of Haplotype 4 (rs55975119), in thiamine-depleted HEK cells containing the H4-WT construct, luciferase expression was significantly lower in response to the combination of the JAK inhibitor fedratinib and thiamine, as compared to the expression driven by the H4-MV construct. Fedratinib is in clinical use e.g., in Wernicke’s encephalopathy and in diabetic patients developing myelofibrosis. It has been shown that fedratinib, by inhibiting the SLC19A3 transporter, prevents the uptake of vitamin B1; thus, thiamine levels have to be normalized before using fedratinib [40,41]. Our results shown here indicate that the presence of the genetic variants in H4 of SLC19A3 may modulate this clinical response.
Since the haplotypes studied in this work are located within intronic regions, protein expression and phenotypic effects are likely to manifest in a tissue-specific manner by epigenetic regulation through variable transcription factors. While proper animal models are currently unavailable for studying this complex regulation and disease connections, human studies in patients with diabetes indicate their potential importance. Porta et al. [8] and Larkin et al. [42] have studied a connection between glucose regulation and SLC19A3 in diabetes, and a potential connection with transcription factors, e.g., Sp1 was noted. Regarding the rs34241868 polymorphism, a potential binding site for the transcription factor KLF13 is present, which competes with the Sp1 transcription factor for binding to GC-boxes. These data suggest that Haplotype 3 may be involved in in vivo glucose metabolism.
A limitation of our study is that we did not include blood thiamine level or erythrocyte transketolase activity measurements. However, based on literature data, the reduction linked to the THTR2 transporter could not be detected in blood samples, only in the cerebrospinal fluid [4]. An additional limitation of this study is the relatively low sample size of each group. We plan to confirm the significant differences observed here by examining a larger group of patients, especially with disease complications (e.g., retinopathy, neuropathy). In spite of these limitations, our work may draw attention to the potential benefits of the administration of complex B vitamins alongside metformin therapy, particularly for individuals harboring these polymorphisms.
4. Materials and Methods
4.1. Bioinformatic Analysis of Candidate SLC19A3 SNPs in T2DM
From the T2D Knowledge Portal (
For the investigation of the transcription factor binding sites (TFBS) we used the matrix scan function of the Regulatory Sequence Analysis Tools (RSAT,
The lead SNP within a given haplotype was identified based on the number of predicted transcription factors capable of binding to the respective genomic region. Additionally, the classification of the region (e.g., predicted enhancer or promoter) was considered, as determined by Ensembl annotations.
4.2. Analysis of Genetic Samples from Patients in the Study
Clinical and laboratory data and blood samples of T2DM patients were obtained from the Drug Research Centre (DRC, Balatonfüred, Hungary). The diagnosis of T2DM was established according to the criteria of the American Diabetes Association (ADA). Based on these criteria, individuals with an HbA1c% exceeding 6% were included in the patient group. The age-matched healthy volunteers were selected from visitors at the clinic not suffering from diabetes or related metabolic diseases. The patients received metformin-based medication [43,44].
The blood samples from AU patients were collected at the National Institute of Locomotor Diseases and Disabilities, (from 1 March 2025 Department of Rheumatology and Immunology, Semmelweis University, Budapest, Hungary). Clinical classification of gout was based on the EULAR criteria. Controls (CTRL) were age-matched healthy volunteers, not suffering of hyperuricemia or gout. The patients received allopurinol-based medication [15].
The study was conducted in accordance with the Declaration of Helsinki and with the permission of the Scientific and Research Committee of the Medical Research Council, Hungary (ETT TUKEB references: 2367-1/2019/EKU and 41006-1/2013/EKU). All methods were performed in accordance with the relevant guidelines and regulations. All control subjects and patients in the study gave informed consent to participate in this research and their privacy and identities were fully protected in the manuscript.
4.3. Genetic Analysis and Vector Construction
Genomic DNA was purified from 300 μL of EDTA-anticoagulated blood samples with Puregene Blood Kit (Qiagen, Hilden, Germany). TaqMan-based qPCR reactions for SLC19A3 SNPs (details see in Table 1) were performed in a StepOnePlus device (Applied Biosystems, Waltham, MA, USA) with premade assay mixes and a master mix (cat. 4371353) from ThermoFisher. TaqMan probe specificity was verified by sequencing.
The dual luciferase assay was only tested in the Haplotype 3 (rs34241868) and Haplotype 4 (rs55975119) regions. For this experiment, different regions of the SLC19A3 gene (Figure S7) were cloned into pMCS-Green-Renilla plasmid (ThermoFisher, Waltham, MA, USA cat: 16152) without additional upstream promoter sequences, by using standard restriction enzyme-based cloning. Sequences were amplified from DNA samples extracted from patients’ DNA carrying the WT or the SNPs in homozygous forms. We used the following primers:
| 1868 For | 5′-CGT CAG AAT TCT TTC CTT CAG TCA TTA TTG C-3′ |
| 1868 Rev | 5′-CGT CGG ATC CCT GAT CTA CGA ATG TAC CC-3 |
| 119 For | 5′-AGC TGA ATT CCA TCT ATC CAG TGA CAA CC-3′ |
| 119 Rev | 5′-CGC TGG ATC CTG AGA CCT AGG ACT ATG C-3′ |
4.4. Cell Lines and Dual Luciferase Assay
HEK293 cells (from a human embryonic kidney kindly gifted from Tamás I. Orbán, HUN-REN TTK) were grown in DMEM medium with high glucose and GlutaMax (Gibco, ThermoFisher, Waltham, MA, USA, cat. 31966021) completed with 10% FBS (Gibco, ThermoFisher, Waltham, MA, USA, cat. 10500064) and 0.1% gentamycin (Gibco, ThermoFisher, Waltham, MA, USA, cat. 15710080) at 37 °C (5% CO2). Thiamine-depleted HEK293 cells were grown in M199 medium (Gibco, ThermoFisher, Waltham, MA, USA, cat. 41150020) completed with 10% FBS and 0.1% gentamycin at 37 °C (5% CO2). This latter medium (thiamine concentration: 0.03 µM) contains about 400 times less thiamine-hydrochloride compared to the basic medium (thiamine concentration: 11.9 µM). Since FBS may also contain a small but variable amount of vitamin B1, the same amount of FBS was added from the same lot number of the product to each media. MCF7 cells (a human breast cancer cell line gifted from Gergő Szakács, HUN-REN TTK) were grown in RPMI medium with high glucose and GlutaMax (Gibco, Waltham, MA, USA, cat. 61870010) completed with 10% FBS and 0.1% gentamycin at 37 °C (5% CO2). Transient transfection of HEK293 and MCF7 cells was carried out with Turbofect (ThermoFisher, Waltham, MA, USA, cat. R0531), according to the manufacturers’ protocol.
Drug treatments were carried out 24 h after transfection in completed DMEM medium. The cells were subjected to 10 µM thiamine-hydrochloride (Sigma-Aldrich-Merck, St. Louis, MO, USA, cat T4625), 5µM fedratinib (Selleckchem, Houston, TX, USA, cat. S2736) or 1,1-Dimethylbiguanide hydrochloride (metformin, Sigma-Aldrich-Merck, St. Louis, MO, USA, cat. D150959) for 24 h prior to the experiments.
The dual-luciferase reporter assay system (Pierce, ThermoFisher, Waltham, MA, USA, cat. 16185) was used according to the manufacturer’s guidelines for 96-well cultured cells. Reagents were added manually in 96-well white plates to the cell lysates, and incubated for 3 min at room temperature in the dark before reading the signals in a VictorX3 Multilabel Plate Reader (Perkin-Elmer, Waltham, MA, USA). At least four technical and three biological parallels were performed in all cases. The data were normalized to pCMV-Red-Firefly signals (vector from ThermoFisher, Waltham, MA, USA, cat. 16156).
4.5. Statistical Analysis
The clinical and laboratory data are expressed as mean ± standard error (SD). Statistical analysis was conducted by GraphPad Prism (version 8.0.1, GraphPad Software, Boston, MA, USA). Normal distribution of the variables was checked by an Anderson–Darling test. The physical parameters, such as height, weight, BMI, abdominal circumference, showed a normal distribution, and in these cases the Student t test (2-group analysis) or ANOVA (multigroup analysis) statistical tests were used. The investigated laboratory parameters did not show a normal distribution, so in these cases the Mann–Whitney U test (2 groups) or Kruskal–Wallis (in the case of multigroups) analysis was used. Two component analyses (Student t test or Mann–Whitney U test) were used if the p values of multigroup analyses (ANOVA or Kruskal–Wallis tests) were below 0.1. The level of significance was set at p < 0.05. The number of patients (n) involved in each analysis is indicated in the respective tables.
5. Conclusions
Our study provides novel insights into the genetic and functional relevance of SLC19A3 variants in metabolic diseases, particularly type 2 diabetes and gout. We were the first to identify the four major haplotypes in this gene, determine the lead SNPs of the minor variants, and explore potential transcription factor binding sites. Through genetic association studies, and functional assays, we identified significant correlations between specific SLC19A3 haplotypes and key metabolic parameters. We identified haplotypes H3-MV and H4-MV as potential modulators of glucose metabolism, uric acid levels, and immune cell profiles, suggesting a role for SLC19A3 in studied diseases pathophysiology. The increased gene expression observed in H3-MV carrier cells under thiamine depletion and metformin treatment further supports the functional relevance of these variants in cellular responses to metabolic stress. Similarly, the H4 minor variant showed sensitivity to fedratinib treatment in thiamine-depleted conditions, further highlighting the clinical relevance of these polymorphisms. While our findings underscore the potential role of SLC19A3 in metabolic regulation, larger patient cohorts and additional in vitro studies are needed to fully elucidate the impact of these variants on studied diseases development and treatment responses. Our results suggest that personalized approaches, including targeted vitamin B1 supplementation, may be beneficial for individuals carrying these genetic variants, particularly in the context of metformin therapy for diabetes and potential immune modulation in gout.
E.S. designed and performed the experiments, analyzed the data, B.B. performed the bioinformatic analysis, B.L.-N., L.K., M.P. and G.P. provided and reviewed the clinical data. E.S., G.V. and B.S. contributed to the writing and critically revised the manuscript. All authors read and approved the final version. All authors have read and agreed to the published version of the manuscript.
The study was conducted in accordance with the Declaration of Helsinki and with the permission of the Scientific and Research Committee of the Medical Research Council, Hungary (ETT TUKEB references: 2367-1/2019/EKU and 41006-1/2013/EKU). All methods were performed in accordance with the relevant guidelines and regulations.
All control subjects and patients in the study gave informed consent to participate in this research and their privacy and identities were fully protected in the manuscript.
The datasets generated and analyzed during the current study are available from the corresponding authors on reasonable request.
We thank K. Hupcsik and A. Füredi for helping with the cell lines.
The authors declare that they have no conflicts of interest.
| 1000 G | 1000 Genomes |
| ABCG2 | ATP binding cassette G2 |
| ADA | American Diabetes Association |
| Arid5a | AT-Rich Interaction Domain 5A |
| AU | arthritis urica, gout |
| BMI | body mass index |
| CTRL | control |
| DDIT3 | DNA damage-inducible transcript 3 |
| DNA | deoxyribonucleic acid |
| EBF genes | early B-cell factors |
| ESR | erythrocyte sedimentation rates |
| ESR2 | Estrogen Receptor 2 |
| Fedra | fedratinib |
| FoxB1 | Forkhead Box B1 |
| GATA-1 | GATA-BINDING PROTEIN 1 |
| HbA1c | hemoglobin A1C |
| HOMA | Homeostasis Model Assessment |
| HOX genes | subset of homeobox genes |
| HWE | Hardy–Weinberg equilibrium |
| IRF9 | Interferon regulatory factor 9 |
| JAK | Janus kinase |
| KLF13 | Kruppel-like transcription factor 13 |
| LD | linkage disequilibrium |
| MAF | minor allele frequency |
| met | metformin |
| MV | minor variant |
| NR1H4 | nuclear receptor subfamily 1 group H member 4 |
| NR2C1 | nuclear receptor subfamily 2, group C, member 1 |
| NR3C1 | nuclear receptor subfamily 3, group C, member 1 |
| NR3C2 | nuclear receptor subfamily 3, group C, member 2 |
| PROX1 | Prospero homeobox protein 1 |
| PWM | position weight matrices |
| RAX2 | Retina And Anterior Neural Fold Homeobox 2 |
| RBC | red blood cells |
| RFX1 | Regulatory Factor X1 |
| RORC | RAR-related orphan receptor gamma |
| SD | standard deviation |
| SLC19A3 | solute carrier 19A3 |
| SNP | single nucleotide polymorphisms |
| SP1 | specificity protein 1* |
| STAT1 | Signal transducer and activator of transcription 1 |
| STAT5 | Signal transducer and activator of transcription 5 |
| T2DM | type 2 diabetes |
| TF | transcription factor |
| TFBS | transcription factor binding sites |
| THTR2 | thiamine transporter-2 |
| UA | uric acid |
| URAT1 | urate transporter 1 |
| WBC | white blood cells |
| WT | wild type |
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 1. Schematic diagram of the location of the four haplotypes examined. The gene map of SLC19A3 is from the Ensembl database. H1: Haplotype 1, H2: Haplotype 2, H3: Haplotye 3, H4: Haplotype 4.
![View Image - Figure 2. HOMA index, and HbA1c% in the presence of the rs34241868 (Haplotype 3) minor variant (both hetero- and homozygotes), in the groups of CTRL individuals and T2DM patients, respectively. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05. CTRL: control, T2DM: type 2 diabetes mellitus, WT: wild type, MV: minor variant, HOMA: Homeostasis Model Assessment, HbA1c%: hemoglobin A1c%.](https://media.proquest.com/media/hms/THUM/4/7E2Fc?_a=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%3D%3D&_s=gTT292Q7UBm0k859rxjwY4bZu6M%3D "View Image - Figure 2. HOMA index, and HbA1c% in the presence of the rs34241868 (Haplotype 3) minor variant (both hetero- and homozygotes), in the groups of CTRL individuals and T2DM patients, respectively. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05. CTRL: control, T2DM: type 2 diabetes mellitus, WT: wild type, MV: minor variant, HOMA: Homeostasis Model Assessment, HbA1c%: hemoglobin A1c%.")
Enlarge this image.Figure 2. HOMA index, and HbA1c% in the presence of the rs34241868 (Haplotype 3) minor variant (both hetero- and homozygotes), in the groups of CTRL individuals and T2DM patients, respectively. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05. CTRL: control, T2DM: type 2 diabetes mellitus, WT: wild type, MV: minor variant, HOMA: Homeostasis Model Assessment, HbA1c%: hemoglobin A1c%.
![View Image - Figure 3. Uric acid levels and white blood cell (WBC) count in the presence of the rs355975119 (haplotype 4) variant (both hetero- and homozygotes), in the groups of CTRL individuals and T2DM patient. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05, *** p [less than] 0.001. CTRL: control, T2DM: type 2 diabetes mellitus, WT: wild type, MV: minor variant, WBC: white blood cells.](https://media.proquest.com/media/hms/THUM/6/7E2Fc?_a=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%3D%3D&_s=uP%2B%2FuxRAwyq2ojNwhnWVIMpoEBg%3D "View Image - Figure 3. Uric acid levels and white blood cell (WBC) count in the presence of the rs355975119 (haplotype 4) variant (both hetero- and homozygotes), in the groups of CTRL individuals and T2DM patient. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05, *** p [less than] 0.001. CTRL: control, T2DM: type 2 diabetes mellitus, WT: wild type, MV: minor variant, WBC: white blood cells.")
Enlarge this image.Figure 3. Uric acid levels and white blood cell (WBC) count in the presence of the rs355975119 (haplotype 4) variant (both hetero- and homozygotes), in the groups of CTRL individuals and T2DM patient. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05, *** p [less than] 0.001. CTRL: control, T2DM: type 2 diabetes mellitus, WT: wild type, MV: minor variant, WBC: white blood cells.
![View Image - Figure 4. Basophil% in the presence of the rs34241868 (haplotype 3) variant (both hetero- and homozygotes), in the groups of CTRL individuals and gout patient. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05. CTRL: control, AU: gout, WT: wild type, MV: minor variant.](https://media.proquest.com/media/hms/THUM/8/7E2Fc?_a=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%3D%3D&_s=wDgPEZvm9y5FhJSfwwR2jct1PNg%3D "View Image - Figure 4. Basophil% in the presence of the rs34241868 (haplotype 3) variant (both hetero- and homozygotes), in the groups of CTRL individuals and gout patient. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05. CTRL: control, AU: gout, WT: wild type, MV: minor variant.")
Enlarge this image.Figure 4. Basophil% in the presence of the rs34241868 (haplotype 3) variant (both hetero- and homozygotes), in the groups of CTRL individuals and gout patient. Values are expressed as mean ± SD. The n values belonging to each group are shown in the column graphs. The p values are calculated by the Mann–Whitney U test. * p [less than] 0.05. CTRL: control, AU: gout, WT: wild type, MV: minor variant.
![View Image - Figure 5. Evaluation of the dual-luciferase assay results. The ratio of the Renilla/normalized Firefly luciferase activity is shown (mean ± SD, n = 3, unpaired two-tailed t test). (A) The effects of Haplotype 3, rs34241868 on luciferase activity. The WT or the rs34241868 versions of the SLC19A3 H3 regions are expressed in HEK293 cells. (B) The role of selected treatments in modulating Renilla luciferase expression in the dual-luciferase assay, performed in thiamine-depleted HEK293 cells. TK: thymidine kinase promoter-containing control vector WT: wild type, MV: minor variant, B1: Vitamin B1, Fedra: fedratinib, Met: metformin * p [less than] 0.05, ** p [less than] 0.01.](https://media.proquest.com/media/hms/THUM/10/7E2Fc?_a=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%3D%3D&_s=191mTxLxsGaqY8dxlzNqBznZ6LU%3D "View Image - Figure 5. Evaluation of the dual-luciferase assay results. The ratio of the Renilla/normalized Firefly luciferase activity is shown (mean ± SD, n = 3, unpaired two-tailed t test). (A) The effects of Haplotype 3, rs34241868 on luciferase activity. The WT or the rs34241868 versions of the SLC19A3 H3 regions are expressed in HEK293 cells. (B) The role of selected treatments in modulating Renilla luciferase expression in the dual-luciferase assay, performed in thiamine-depleted HEK293 cells. TK: thymidine kinase promoter-containing control vector WT: wild type, MV: minor variant, B1: Vitamin B1, Fedra: fedratinib, Met: metformin * p [less than] 0.05, ** p [less than] 0.01.")
Enlarge this image.Figure 5. Evaluation of the dual-luciferase assay results. The ratio of the Renilla/normalized Firefly luciferase activity is shown (mean ± SD, n = 3, unpaired two-tailed t test). (A) The effects of Haplotype 3, rs34241868 on luciferase activity. The WT or the rs34241868 versions of the SLC19A3 H3 regions are expressed in HEK293 cells. (B) The role of selected treatments in modulating Renilla luciferase expression in the dual-luciferase assay, performed in thiamine-depleted HEK293 cells. TK: thymidine kinase promoter-containing control vector WT: wild type, MV: minor variant, B1: Vitamin B1, Fedra: fedratinib, Met: metformin * p [less than] 0.05, ** p [less than] 0.01.
![View Image - Figure 6. Evaluation of the dual-luciferase assay results. The role of selected treatments in modulating Renilla luciferase expression in the dual-luciferase assay, performed in thiamine-depleted HEK293 cells. The effects of rs55975119 on luciferase activity. The ratio of the Renilla/normalized Firefly luciferase activity is shown (mean ± SD, n = 3, unpaired two-tailed t test). WT: wild type, MV: minor variant, B1: Vitamin B1, Fedra: fedratinib, Met: metformin. * p [less than] 0.05.](https://media.proquest.com/media/hms/THUM/12/7E2Fc?_a=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%3D%3D&_s=k9VxBKlaUDvoTKBmE4HpCIS6jOQ%3D "View Image - Figure 6. Evaluation of the dual-luciferase assay results. The role of selected treatments in modulating Renilla luciferase expression in the dual-luciferase assay, performed in thiamine-depleted HEK293 cells. The effects of rs55975119 on luciferase activity. The ratio of the Renilla/normalized Firefly luciferase activity is shown (mean ± SD, n = 3, unpaired two-tailed t test). WT: wild type, MV: minor variant, B1: Vitamin B1, Fedra: fedratinib, Met: metformin. * p [less than] 0.05.")
Enlarge this image.Figure 6. Evaluation of the dual-luciferase assay results. The role of selected treatments in modulating Renilla luciferase expression in the dual-luciferase assay, performed in thiamine-depleted HEK293 cells. The effects of rs55975119 on luciferase activity. The ratio of the Renilla/normalized Firefly luciferase activity is shown (mean ± SD, n = 3, unpaired two-tailed t test). WT: wild type, MV: minor variant, B1: Vitamin B1, Fedra: fedratinib, Met: metformin. * p [less than] 0.05.
SNPs and DNA sequences of the probes used in qPCR experiments.
| SNP | Assay ID | Context Sequence [VIC/FAM] |
|---|---|---|
| rs6436729 | C__26173496_10 | GCATGGTGGTATATGCCTGTAGTCC[T/A]AGCTACTGAGAAGCTGAGGCAGGAA |
| rs34241868 | C__32730488_10 | AGAATATACCCCACACCTGAACAGA[C/A]CCATTCACAAGATAATGTAGCTTAT |
| rs55975119 | C__88465680_10 | TCTCACTTCCTAGCTGCATGCCTTA[A/C]AGGACAGAAAGGTCCTCAGATCTCC |
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Sechi, G.; Serra, A. Wernicke’s Encephalopathy: New Clinical Settings and Recent Advances in Diagnosis and Management. Lancet Neurol.; 2007; 6, pp. 442-455. [DOI: https://dx.doi.org/10.1016/S1474-4422(07)70104-7] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17434099]
2. Tóth, A.; Aradi, G.; Várallyay, G.; Arányi, Z.; Bereczki, D.; Vastagh, I. Wernicke’s Encephalopathy Induced by the Use of Diet Pills and Unbalanced Diet. Orv. Hetil.; 2014; 155, pp. 469-474. [DOI: https://dx.doi.org/10.1556/OH.2014.29847] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24631935]
3. Ziegler, D.; Reiners, K.; Strom, A.; Obeid, R. Association between Diabetes and Thiamine Status—A Systematic Review and Meta-Analysis. Metabolism; 2023; 144, 155565. [DOI: https://dx.doi.org/10.1016/j.metabol.2023.155565] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37094704]
4. Marcé-Grau, A.; Martí-Sánchez, L.; Baide-Mairena, H.; Ortigoza-Escobar, J.D.; Pérez-Dueñas, B. Genetic Defects of Thiamine Transport and Metabolism: A Review of Clinical Phenotypes, Genetics, and Functional Studies. J. Inherit. Metab. Dis.; 2019; 42, pp. 581-597. [DOI: https://dx.doi.org/10.1002/jimd.12125]
5. Koepsell, H. Organic Cation Transporters in Health and Disease. Pharmacol. Rev.; 2020; 72, pp. 253-319. [DOI: https://dx.doi.org/10.1124/pr.118.015578]
6. Beltramo, E.; Mazzeo, A.; Porta, M. Thiamine and Diabetes: Back to the Future?. Acta Diabetol.; 2021; 58, pp. 1433-1439. [DOI: https://dx.doi.org/10.1007/s00592-021-01752-4]
7. Zera, K.; Sweet, R.; Zastre, J. Role of HIF-1α in the Hypoxia Inducible Expression of the Thiamine Transporter, SLC19A3. Gene; 2016; 595, pp. 212-220. [DOI: https://dx.doi.org/10.1016/j.gene.2016.10.013]
8. Porta, M.; Toppila, I.; Sandholm, N.; Hosseini, S.M.; Forsblom, C.; Hietala, K.; Borio, L.; Harjutsalo, V.; Klein, B.E.; Klein, R. et al. Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes. Diabetes; 2016; 65, pp. 1022-1030. [DOI: https://dx.doi.org/10.2337/db15-1247]
9. Mazzeo, A.; Barutta, F.; Bellucci, L.; Trento, M.; Gruden, G.; Porta, M.; Beltramo, E. Reduced Thiamine Availability and Hyperglycemia Impair Thiamine Transport in Renal Glomerular Cells through Modulation of Thiamine Transporter 2. Biomedicines; 2021; 9, 385. [DOI: https://dx.doi.org/10.3390/biomedicines9040385]
10. Beltramo, E.; Mazzeo, A.; Lopatina, T.; Trento, M.; Porta, M. Thiamine Transporter 2 Is Involved in High Glucose-Induced Damage and Altered Thiamine Availability in Cell Models of Diabetic Retinopathy. Diabetes Vasc. Dis. Res.; 2020; 17, 147916411987842. [DOI: https://dx.doi.org/10.1177/1479164119878427]
11. Liang, X.; Chien, H.-C.; Yee, S.W.; Giacomini, M.M.; Chen, E.C.; Piao, M.; Hao, J.; Twelves, J.; Lepist, E.-I.; Ray, A.S. et al. Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol. Pharm.; 2015; 12, pp. 4301-4310. [DOI: https://dx.doi.org/10.1021/acs.molpharmaceut.5b00501] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26528626]
12. Liang, X.; Giacomini, K.M. Transporters Involved in Metformin Pharmacokinetics and Treatment Response. J. Pharm. Sci.; 2017; 106, pp. 2245-2250. [DOI: https://dx.doi.org/10.1016/j.xphs.2017.04.078] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28495567]
13. Yamashiro, T.; Yasujima, T.; Said, H.M.; Yuasa, H. PH-Dependent Pyridoxine Transport by SLC19A2 and SLC19A3: Implications for Absorption in Acidic Microclimates. J. Biol. Chem.; 2020; 295, pp. 16998-17008. [DOI: https://dx.doi.org/10.1074/jbc.RA120.013610] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33008889]
14. Li, X.; Li, L.; Xing, Y.; Cheng, T.; Ren, S.; Ma, H. Diabetes Mellitus Is Associated with a Lower Risk of Gout: A Meta-Analysis of Observational Studies. J. Diabetes Res.; 2020; 2020, 5470739. [DOI: https://dx.doi.org/10.1155/2020/5470739]
15. Pálinkás, M.; Szabó, E.; Kulin, A.; Mózner, O.; Rásonyi, R.; Juhász, P.; Nagy, K.; Várady, G.; Vörös, D.; Zámbó, B. et al. Genetic Polymorphisms and Decreased Protein Expression of ABCG2 Urate Transporters Are Associated with Susceptibility to Gout, Disease Severity and Renal-Overload Hyperuricemia. Clin. Exp. Med.; 2022; 23, pp. 1277-1284. [DOI: https://dx.doi.org/10.1007/s10238-022-00848-7]
16. 1000 Genomes Project Consortium Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A. et al. A Global Reference for Human Genetic Variation. Nature; 2015; 526, pp. 68-74. [DOI: https://dx.doi.org/10.1038/nature15393]
17. Hubert, K.A.; Wellik, D.M. Hox Genes in Development and Beyond. Development; 2023; 150, dev192476. [DOI: https://dx.doi.org/10.1242/dev.192476]
18. Kloetzli, J.M.; Fontaine-Glover, I.A.; Brown, E.R.; Kuo, M.; Labosky, P.A. The Winged Helix Gene, Foxb1, Controls Development of Mammary Glands and Regions of the CNS That Regulate the Milk-Ejection Reflex. Genesis; 2001; 29, pp. 60-71. [DOI: https://dx.doi.org/10.1002/1526-968x(200102)29:2<60::aid-gene1006>3.0.co;2-l]
19. De Souza, F.S.J.; Placzek, M. Conserved Roles of Rax/Rx3 Genes in Hypothalamus and Pituitary Development. Int. J. Dev. Biol.; 2021; 65, pp. 195-205. [DOI: https://dx.doi.org/10.1387/ijdb.200081fd]
20. Medina, K.L.; Singh, H. Genetic Networks That Regulate B Lymphopoiesis. Curr. Opin. Hematol.; 2005; 12, pp. 203-209. [DOI: https://dx.doi.org/10.1097/01.moh.0000160735.67596.a0]
21. Ducoli, L.; Detmar, M. Beyond PROX1: Transcriptional, Epigenetic, and Noncoding RNA Regulation of Lymphatic Identity and Function. Dev. Cell; 2021; 56, pp. 406-426. [DOI: https://dx.doi.org/10.1016/j.devcel.2021.01.018] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33621491]
22. Kim, U.; Shin, H.Y. Genomic Mutations of the STAT5 Transcription Factor Are Associated with Human Cancer and Immune Diseases. Int. J. Mol. Sci.; 2022; 23, 11297. [DOI: https://dx.doi.org/10.3390/ijms231911297] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36232600]
23. Issac, J.; Raveendran, P.S.; Das, A. V RFX1: A Promising Therapeutic Arsenal against Cancer. Cancer Cell Int.; 2021; 21, 253. [DOI: https://dx.doi.org/10.1186/s12935-021-01952-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33964962]
24. Cao, D.; Qi, Z.; Pang, Y.; Li, H.; Xie, H.; Wu, J.; Huang, Y.; Zhu, Y.; Shen, Y.; Zhu, Y. et al. Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. Cancer Res.; 2019; 79, pp. 2604-2618. [DOI: https://dx.doi.org/10.1158/0008-5472.CAN-18-3842]
25. Chiang, J.Y.L.; Ferrell, J.M. Discovery of Farnesoid X Receptor and Its Role in Bile Acid Metabolism. Mol. Cell. Endocrinol.; 2022; 548, 111618. [DOI: https://dx.doi.org/10.1016/j.mce.2022.111618]
26. Wachowski, N.A.; Pippin, J.A.; Boehm, K.; Lu, S.; Leonard, M.E.; Manduchi, E.; Parlin, U.W.; Wabitsch, M.; Chesi, A.; Wells, A.D. et al. Implicating Type 2 Diabetes Effector Genes in Relevant Metabolic Cellular Models Using Promoter-Focused Capture-C. Diabetologia; 2024; 67, pp. 2740-2753. [DOI: https://dx.doi.org/10.1007/s00125-024-06261-x]
27. Sun, Y.; Demagny, H.; Schoonjans, K. Emerging Functions of the Nuclear Receptor LRH-1 in Liver Physiology and Pathology. Biochim. Biophys. Acta-Mol. Basis Dis.; 2021; 1867, 166145. [DOI: https://dx.doi.org/10.1016/j.bbadis.2021.166145]
28. Daniel, S.; Kim, K.-H. Sp1 Mediates Glucose Activation of the Acetyl-CoA Carboxylase Promoter. J. Biol. Chem.; 1996; 271, pp. 1385-1392. [DOI: https://dx.doi.org/10.1074/jbc.271.3.1385]
29. Yang, S.; Xiang, J.; Ma, C.; Yang, G.; Wang, X.; Liu, H.; Fan, G.; Kang, L.; Liang, Z. Sp1-like Protein KLF13 Acts as a Negative Feedback Regulator of TGF-β Signaling and Fibrosis. Cell Rep.; 2023; 42, 112367. [DOI: https://dx.doi.org/10.1016/j.celrep.2023.112367]
30. Frank, A.; Brown, L.M.; Clegg, D.J. The Role of Hypothalamic Estrogen Receptors in Metabolic Regulation. Front. Neuroendocrinol.; 2014; 35, pp. 550-557. [DOI: https://dx.doi.org/10.1016/j.yfrne.2014.05.002]
31. Morales, M.; Martín-Vasallo, P.; Ávila, J. Genetic Profiling of Glucocorticoid (NR3C1) and Mineralocorticoid (NR3C2) Receptor Polymorphisms before Starting Therapy with Androgen Receptor Inhibitors: A Study of a Patient Who Developed Toxic Myocarditis after Enzalutamide Treatment. Biomedicines; 2022; 10, 1271. [DOI: https://dx.doi.org/10.3390/biomedicines10061271] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35740293]
32. Simon, M.C. Transcription Factor GATA-1 and Erythroid Development. Exp. Biol. Med.; 1993; 202, pp. 115-121. [DOI: https://dx.doi.org/10.3181/00379727-202-43519A] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8424101]
33. Berastegui, N.; Ainciburu, M.; Romero, J.P.; Garcia-Olloqui, P.; Alfonso-Pierola, A.; Philippe, C.; Vilas-Zornoza, A.; San Martin-Uriz, P.; Ruiz-Hernández, R.; Abarrategi, A. et al. The Transcription Factor DDIT3 Is a Potential Driver of Dyserythropoiesis in Myelodysplastic Syndromes. Nat. Commun.; 2022; 13, 7619. [DOI: https://dx.doi.org/10.1038/s41467-022-35192-7] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36494342]
34. Tolomeo, M.; Cavalli, A.; Cascio, A. STAT1 and Its Crucial Role in the Control of Viral Infections. Int. J. Mol. Sci.; 2022; 23, 4095. [DOI: https://dx.doi.org/10.3390/ijms23084095]
35. Nyati, K.K.; Zaman, M.M.-U.; Sharma, P.; Kishimoto, T. Arid5a, an RNA-Binding Protein in Immune Regulation: RNA Stability, Inflammation, and Autoimmunity. Trends Immunol.; 2020; 41, pp. 255-268. [DOI: https://dx.doi.org/10.1016/j.it.2020.01.004]
36. Paul, A.; Tang, T.H.; Ng, S.K. Interferon Regulatory Factor 9 Structure and Regulation. Front. Immunol.; 2018; 9, 1831. [DOI: https://dx.doi.org/10.3389/fimmu.2018.01831]
37. Minematsu, T.; Giacomini, K.M. Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins. Mol. Cancer Ther.; 2011; 10, pp. 531-539. [DOI: https://dx.doi.org/10.1158/1535-7163.MCT-10-0731]
38. Mofo Mato, E.P.; Guewo-Fokeng, M.; Essop, M.F.; Owira, P.M.O. Genetic Polymorphisms of Organic Cation Transporter 1 (OCT1) and Responses to Metformin Therapy in Individuals with Type 2 Diabetes: A Systematic Review. Medicine; 2018; 97, e11349. [DOI: https://dx.doi.org/10.1097/MD.0000000000011349]
39. Yu, H.; Xue, W.; Yu, H.; Gu, H.; Qin, L.; Peng, A. Joint Application of Multiple Inflammatory Cytokines in Diagnosis of Gout Flare. J. Inflamm. Res.; 2023; 16, pp. 1771-1782. [DOI: https://dx.doi.org/10.2147/JIR.S408929]
40. England, J.T.; Gupta, V. Fedratinib: A Pharmacotherapeutic Option for JAK-Inhibitor Naïve and Exposed Patients with Myelofibrosis. Expert Opin. Pharmacother.; 2022; 23, pp. 1677-1686. [DOI: https://dx.doi.org/10.1080/14656566.2022.2135989]
41. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Fedratinib; 2012; Available online: https://pubmed.ncbi.nlm.nih.gov/34633785/ (accessed on 23 June 2020).
42. Larkin, J.R.; Zhang, F.; Godfrey, L.; Molostvov, G.; Zehnder, D.; Rabbani, N.; Thornalley, P.J. Glucose-Induced Down Regulation of Thiamine Transporters in the Kidney Proximal Tubular Epithelium Produces Thiamine Insufficiency in Diabetes. PLoS ONE; 2012; 7, e53175. [DOI: https://dx.doi.org/10.1371/journal.pone.0053175]
43. Szabó, E.; Kulin, A.; Mózner, O.; Korányi, L.; Literáti-Nagy, B.; Vitai, M.; Cserepes, J.; Sarkadi, B.; Várady, G. Potential Role of the ABCG2-Q141K Polymorphism in Type 2 Diabetes. PLoS ONE; 2021; 16, e0260957. [DOI: https://dx.doi.org/10.1371/journal.pone.0260957]
44. Szabó, E.; Kulin, A.; Korányi, L.; Literáti-Nagy, B.; Cserepes, J.; Somogyi, A.; Sarkadi, B.; Várady, G. Alterations in Erythrocyte Membrane Transporter Expression Levels in Type 2 Diabetic Patients. Sci. Rep.; 2021; 11, 2765. [DOI: https://dx.doi.org/10.1038/s41598-021-82417-8]
45. Bartáková, V.; Pleskačová, A.; Kuricová, K.; Pácal, L.; Dvořáková, V.; Bělobrádková, J.; Tomandlová, M.; Tomandl, J.; Kaňková, K. Dysfunctional Protection against Advanced Glycation Due to Thiamine Metabolism Abnormalities in Gestational Diabetes. Glycoconj. J.; 2016; 33, pp. 591-598. [DOI: https://dx.doi.org/10.1007/s10719-016-9688-9]
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Pálinkás, Márton 2 ; Bohár, Balázs 3 ; Literáti-Nagy, Botond 4
; Korányi, László 4 ; Poór, Gyula 2 ; Várady, György 5
; Sarkadi, Balázs 5
1 Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary;
2 Department of Rheumatology and Immunology, Semmelweis University, 1023 Budapest, Hungary;
3 Doctoral School of Biology, Eötvös Loránd University, 1117 Budapest, Hungary;
4 Drug Research Center, 8230 Balatonfüred, Hungary;
5 Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary;